Baroda Rayon (500270)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 8.08 and P/B of 1.17 indicate the stock is not priced for high growth, leaving limited expectations embedded.
• Book value per share of ₹155.28 provides a partial downside cushion against the current price of ₹181.75.
• ROE of 12.14% suggests equity holders earn a reasonable return on stated book value.
• Latest quarter net profit of ₹4 Cr on sales of ₹13 Cr implies a strong profit margin on that small base.

Concerns

• Sales declined 16.29% and profit fell 10.09%, showing a shrinking business rather than a compounding one.
• Piotroski F-Score of 3/9 signals weak financial health and poor fundamental momentum.
• ROCE of only 5.04% is far below ROE, indicating poor capital efficiency and the likely influence of leverage or non-operating gains.
• Annualising latest quarter profit gives only about ₹16 Cr, far below the ~₹51 Cr implied by the trailing P/E, raising earnings quality concerns.

AI Analysis

At ₹181.75, Baroda Rayon is priced like a bargain, but I have learned that a low number can hide a troubled business. The P/E is 8.08 and the P/B is 1.17, with book value at ₹155.28, so the market is paying a modest premium to stated net assets. Fine, but I don't buy assets; I buy future earnings with a margin of safety. Here, sales are down 16.29% and profits are down 10.09%. The latest quarter shows only ₹13 Cr of sales and ₹4 Cr of net profit. Annualise that profit and you get roughly ₹16 Cr, which is far below what the trailing P/E suggests. That gap tells me earnings quality is questionable, perhaps from one-off gains or inconsistent project recognition. ROE of 12.14% looks acceptable, but ROCE of only 5.04% warns that the operating business generates weak returns; the gap likely comes from financial leverage or non-operating items. The Piotroski score of 3 out of 9 is a giant red flag. A healthy business would score much higher. There is no dividend to compensate me while I wait. This looks like a cyclical, capital-intensive project business with lumpy revenues, not a compounding machine. Graham would demand hard evidence of sustainable earning power, a strong balance sheet, and honest asset values. I don't see that here. The price sits at the top of its 52-week range, so optimism has already crept in. In this situation, I would rather miss the move than risk my capital. For a retail investor, Baroda Rayon belongs in the 'too hard' pile unless project execution, cash flows, and return on capital clearly improve.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer